Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.20 | 1.30 | -0.01% |
| CAC 40 | 7,891.00 | 5.93 | -0.08% |
| DAX 40 | 23,625.14 | 123.72 | -0.52% |
| Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
| FTSE 100 | 9,257.03 | 20.00 | -0.22% |
| HKSE | 26,438.51 | 8.05 | -0.03% |
| NASDAQ | 22,348.75 | 207.64 | 0.94% |
| Nikkei 225 | 44,902.27 | 134.15 | 0.30% |
| NZX 50 Index | 13,234.89 | 26.58 | 0.20% |
| S&P 500 | 6,615.28 | 30.99 | 0.47% |
| S&P/ASX 200 | 8,877.70 | 3.00 | -0.03% |
| SSE Composite Index | 3,861.86 | 1.36 | 0.04% |